Chemosensitivity and chemoresistance testing in ovarian cancer
Chemosensitivity and chemoresistance testing in ovarian cancer
复制标题
DOI：
10.1097/gco.0b013e32832210ff
复制
发表时间：
2009-02-01
影响因子：
2.1
通讯作者：
Cree, Ian A.
中科院分区：
文献类型：
--
作者：
Cree, Ian A.
卵巢癌个体化治疗的敏感性检测仍然是一个活跃的研究领域，最近几个研究组的结果又重新提出了这一点。检测导向治疗的临床结果总是好于经验性治疗的预期，但事实证明，这些检测很难付诸实践。最近的研究结果最近的几项研究表明，细胞个体化肿瘤反应检测，特别是基于ATP的肿瘤化疗敏感性检测，可以提高个体患者的反应机会和生存率。大多数肿瘤反应试验显示出与临床耐药性的良好相关性，但其预测敏感性的能力各不相同。卵巢癌的敏感性和耐药性的分子检测不如乳腺癌发达，但那些使用多个基因签名显示出相当大的希望，总结个体化治疗有能力指导化疗以及更新的药物的使用。用于卵巢癌的药物的伴随诊断的发展在未来具有相当大的潜力，并且这种测定已经证明在可能的治疗之间存在等效性的临床证据的情况下是有用的。关键词
Purpose of reviewSensitivity testing in ovarian cancer to individualize therapy remains an active area of interest and this has been renewed recently by results from several groups. The clinical results of assay-directed therapy are invariably better than would be expected from empirical treatment, but it has proved difficult to get these tests into practice,Recent findingsSeveral recent studies suggest that cellular individualized tumour response tests, particularly the ATP-based tumour chemosensitivity assay, can improve the chance of response and probably survival for individual patients. Most tumour response tests show excellent correlation with clinical resistance, but vary in their ability to predict sensitivity. Molecular assays of sensitivity and resistance are less developed in ovarian cancer than in breast cancer, but those using multiple gene signatures show considerable promise,SummaryIndividualized therapy has the ability to guide the use of chemotherapy as well as newer agents. The development of companion diagnostics for drugs used in ovarian cancer has considerable potential for the future and such assays are already proving useful where there is clinical evidence of equivalence between possible treatments. Keywords